Referanser

1. Ljungberg B., Hanbury D.C., Kuczyk M.A., MerseburgerA.S., Mulders P.F.A., Patard J-J.,Sinescu I.C. Guidelines on Renal Cell Carcinoma. European Assiociation of Urology 2006.
2. Kåresen, Rolf. Wist, Erik (red.). Kreftsykdommer - en basisbok for helsepersonell. 2.7 Svulster i nyre, blære og urinveiene, s 218 - 221. Gyldendal Norsk Forlag 2005.
3. TNM Atlas. Illustrated Guide to the TNM/pTNM Classification of Malignant Tumours. 5th Edition 2004.
4. Enquist, E., Walther, M.M., Linehan, W.M. Molecular genetics of renal cell carcinoma. Publisching in Renal, bladder and prostate cancer an update. The Proceedings of til V Congress on Progress and Controversies in Oncological Urology, October 1998. P 5 - 11.
5. Ljungberg, B. Alamdari, FI. Rasmuson, T. Roos, G. Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. BJU Int 1999; 84 (4): 405-11.
6. Larsen, Erik Højkjær. Frimodt-Møller, Poul Chr. Horn, Thomas. Dorph, Sven. Maase, Hans von der. Nyrecancer. Betænkning fra arbejdsgruppe nedsat af Dansk Urologisk Selskab. Ugeskrift for læger, Nr. 7, 2002.
7. Chiu, BC. Gapstur, SM. Chow, WH. Kirby, KA. Lynch, CF. Cantor, KP. Body mass index, physical activity, and risk of renal cell carcinoma. Department of Preventive Medicine, Northwestern University Medical School, Chicago, IL,USA.PubMed. PMID:16446746
8. Pischon, T. Lahmann, PH. Boeing, H. Tjonneland, A. Halkjaer, J. Overvad, K. et. al. Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC). Department of Epidemiology, German Institute of Human Nutrition, Potsdam-Rehbruecke, Germany. PubMed. PMID: 1609462
9. VISS Vårdinformasjon StorStockholm, Vårdprogram, njurcancer. www.viss.nu/default.HTM
10. Sandock, DS. Seftel, AD. Resnick, MI. A new protocol for the followup of renal cell carcinoma based on pathological stage. J Urol 1995; 154: 28-31.
11. Levy, DA. Slaton, JW. Swanson, DA. Dinney, CP. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol 1998; 159 (4): 1163-7.
12. Lindblad, P. Epidemiology of renal cell carcinoma. Scand J Surg 2004; 93: 88-96. PubMed. PMID: 15285559.
13. Hudes G. Carduzzi, M. Tomczak, P. Dutcher, J. Figlin, R. Kapoor et. al. A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No 18S (June 20 Supplement), 2006: LBA4.
14. Motzer, R.J. Hutson, T.E. Tomczak, P. Michaelson, M.D. Bukowski, R.M. Rixe, O. et. al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-a)  first-line systemic terapy for patients with metastatic renal cell carcinoma (mRCC). Journal of Clinica lOncology, 2006 ASCO Annual Meeting Proceedings Part. I. Vol. 24, No. 18S (June 20 Supplement), 2006: LBA3.